Explore

Trendline Trendline
Novo Nordisk Advances Regulatory Filings for Sickle Cell Drug Etavopivat Following Positive Trial Results

Novo Nordisk Advances Regulatory Filings for Sickle Cell Drug Etavopivat Following Positive Trial Results

Novo Nordisk Advances Regulatory Filings for Sickle Cell Drug Etavopivat Following Positive Trial Results
Trendline Trendline
Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer

Inhibrx Announces Webcast for Clinical Update on Ozekibart in Colorectal Cancer
Trendline Trendline
Novo Nordisk Advances Sickle Cell Drug Etavopivat with Promising Trial Results

Novo Nordisk Advances Sickle Cell Drug Etavopivat with Promising Trial Results

Novo Nordisk Advances Sickle Cell Drug Etavopivat with Promising Trial Results
Reuters Reuters
Explainer-What to know about psychedelic therapies cited by Trump

Explainer-What to know about psychedelic therapies cited by Trump

By Nancy Lapid April 21 (Reuters) - U.S.
Trendline Trendline
FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy

FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy

FDA Grants Fast Track Designation to Debiopharm's Ovarian Cancer Therapy
Trendline Trendline
Viatris Recalls Xanax XR Due to Dissolution Test Failure, Affecting U.S. Market

Viatris Recalls Xanax XR Due to Dissolution Test Failure, Affecting U.S. Market

Viatris Recalls Xanax XR Due to Dissolution Test Failure, Affecting U.S. Market
Trendline Trendline
Novo Nordisk Advances Sickle Cell Drug Etavopivat Towards Regulatory Filings

Novo Nordisk Advances Sickle Cell Drug Etavopivat Towards Regulatory Filings

Novo Nordisk Advances Sickle Cell Drug Etavopivat Towards Regulatory Filings
Trendline Trendline
Inhibrx to Provide Clinical Update on Ozekibart for Colorectal Cancer

Inhibrx to Provide Clinical Update on Ozekibart for Colorectal Cancer

Inhibrx to Provide Clinical Update on Ozekibart for Colorectal Cancer
Trendline Trendline
FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment

FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment

FDA Grants Star Therapeutics Rare Pediatric and Breakthrough Therapy Designations for Von Willebrand Disease Treatment
Trendline Trendline
Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment

Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment

Star Therapeutics Gains FDA Designations for VGA039 in Von Willebrand Disease Treatment
Trendline Trendline
Revolution Medicine's Phase III Pancreatic Cancer Trial Results Boost Stock and Investor Confidence

Revolution Medicine's Phase III Pancreatic Cancer Trial Results Boost Stock and Investor Confidence

Revolution Medicine's Phase III Pancreatic Cancer Trial Results Boost Stock and Investor Confidence
Trendline Trendline
Asahi Kasei Initiates Phase I Trial for New Peptide Targeting Autoimmune Diseases

Asahi Kasei Initiates Phase I Trial for New Peptide Targeting Autoimmune Diseases

Asahi Kasei Initiates Phase I Trial for New Peptide Targeting Autoimmune Diseases